Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Pharmacology stubs
LY3372689
Другие языки:

    LY3372689

    Подписчиков: 0, рейтинг: 0
    LY3372689
    LY3372689.png
    Names
    IUPAC name
    N-[4-fluoro-5-[[2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide
    Identifiers
    3D model (JSmol)
    PubChem CID
    • InChI=1S/C16H22FN5O3S/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12H,4-8H2,1-3H3,(H,18,20,23)
      Key: FRVXHWNHGWUTQO-UHFFFAOYSA-N
    • CC(NC1=NC(F)=C(CN2CC[C@H](OCC3=NOC(C)=N3)C[C@@H]2C)S1)=O
    Properties
    C16H22FN5O3S
    Molar mass 383.44 g·mol−1
    Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

    LY3372689 is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme O-GlcNAcase. Its result is to reduce formation of tau protein tangles.

    A molecule containing radioactive fluorine was used with a PET scan to show that LY3372689 binds in the human brain.

    Eli Lilly and Company is recruiting subjects for a clinical trial. Some hospitals in Australia: St Vincent's Hospital, Sydney Hornsby Ku-Ring-Gai Hospital, The Prince Charles Hospital, The Queen Elizabeth Hospital, Adelaide, Box Hill Hospital, and Delmont Private Hospital are involved. Results of the trial are expected by June 2024.

    Chemical

    The molecule contains three rings: thiazole, piperidine and oxadiazole. Other functional groups included are an ether, acetamide, and a fluoride.



    Новое сообщение